Guidance on the optimal use of novel agents for lower-risk and intermediate-risk MDS

0 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Valeria Santini, MD, University of Florence, Florence, Italy, discusses an educational session at the 2025 ASCO meeting focused on the stratification and classification of myelodysplastic syndromes (MDS), as well as the optimal use of novel agents for lower-risk and intermediate-risk MDS. Prof. Santini gives guidance on the use of luspatercept and imetelstat, highlighting subgroups of patients who benefit most from these agents. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Category
Oncology
Be the first to comment

Up Next